Home> Trial Details

Information Clinical trials have complex eligibility criteria.
Always talk to your clinician about you’re interest in participating in a trial.Learn why

Optimise reading forHealth Professionals Patients

RecruitingLast updated:15 August 2023

Magrolimab: This trial is evaluating the addition of a targeted cancer drug (Magrolimab) to chemotherapy (using Nab-Paclitaxel or Paclitaxel) for the treatment of people with triple negative breast cancer that has spread to other parts of the bodyA Phase 2, Randomized, Open-Label Study Evaluating the Safety and Efficacy of Magrolimab in Combination With Nab-Paclitaxel or Paclitaxel Versus Nab-Paclitaxel or Paclitaxel in Previously Untreated Patients With Metastatic Triple-Negative Breast Cancer

Clinical summary Eligibilty Participating hospital Support

Clinical summary

Summary

Eligible participants will include a safety run-in cohort to establish a recommended phase two dose (RP2D) of Magrolimab. Following the safety run-in cohort, eligible participants will be randomised into one of two experimental treatment arms. Participants in one arm will receive the RP2D of Magrolimab in combination with Nab-Paclitaxel (100mg/m^2) or Paclitaxel (90mg/m^2) on Days 1, 8 and 15 of each 28-day treatment cycle. Participants in the other arm won't receive treatment with Magrolimab.

Age

People 18+

Phase

Trial Acronym

Magrolimab

More information

Trial Identifiers

Use the hyperlinks, where available to access additional clinical trial information.

NCT04958785
GS-US-586-6144

Commercial Sponsor

Gilead Sciences

Scientific Title

A Phase 2, Randomized, Open-Label Study Evaluating the Safety and Efficacy of Magrolimab in Combination With Nab-Paclitaxel or Paclitaxel Versus Nab-Paclitaxel or Paclitaxel in Previously Untreated Patients With Metastatic Triple-Negative Breast Cancer

Share with email

Print this page

Download brochure

Eligibility

Inclusion

You have certain types of non-cancer medical conditions.
You have had certain treatments, surgical procedures or drugs.
You have previously been treated (or are currently being treated) on a clinical trial.

Exclusion

Your cancer has spread to other parts of the body.

Clinical trials have complex eligibility criteria.

Ask your doctor if this trial could be right for you.

Participating hospitals

Recruiting hospitals

Information Tell us if you find this trial availability is not accurate.Report inaccuracy